Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Trazodone
Drug ID BADD_D02266
Description Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants.[A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression.[T646] A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy.[T646] Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters.[T646] It was initially granted FDA approval in 1981.[L3484]
Indications and Usage For the treatment of depression.
Marketing Status Prescription; Discontinued
ATC Code N06AX05
DrugBank ID DB00656
KEGG ID D08626
MeSH ID D014196
PubChem ID 5533
TTD Drug ID D00USF
NDC Product Code 51655-634
Synonyms Trazodone | Tradozone | AF-1161 | AF 1161 | AF1161 | Deprax | Desyrel | Gen-Trazodone | Gen Trazodone | Molipaxin | Novo-Trazodone | Novo Trazodone | Trittico | PMS-Trazodone | PMS Trazodone | Ratio-Trazodone | Ratio Trazodone | RatioTrazodone | Thombran | Trazodon Hexal | Trazodon-Neuraxpharm | Trazodon Neuraxpharm | TrazodonNeuraxpharm | Trazodone Hydrochloride | Trazon | Apo-Trazodone | Apo Trazodone | Nu-Trazodone | Nu Trazodone
Chemical Information
Molecular Formula C19H22ClN5O
CAS Registry Number 19794-93-5
SMILES C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyponatraemia14.05.04.0020.000090%
Hypotension24.06.03.0020.000090%
Incontinence07.01.06.011; 20.02.02.004; 17.05.01.006--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukocytosis01.02.01.002--
Libido decreased21.03.02.005; 19.08.03.001--
Libido increased21.03.02.007; 19.08.03.002--
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Mean arterial pressure13.14.03.018--Not Available
Memory impairment19.20.01.003; 17.03.02.003--
Menstruation irregular05.05.01.008; 21.01.01.005--
Mental disability26.01.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Methaemoglobinaemia01.05.01.002--
Micturition urgency20.02.02.006--
Migraine24.03.05.003; 17.14.02.001--Not Available
Miosis06.05.03.003; 17.02.11.002--Not Available
Muscle twitching15.05.03.005--Not Available
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nail discolouration23.02.05.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.0010.000135%
Nervousness19.06.02.003--Not Available
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages